Long-term therapy with bisphosphonates: review of clinical studies
https://doi.org/10.14341/osteo13143
Abstract
The purpose of this scientific literature review was to examine clinical recommendations for the duration of bisphosphonate therapy in patients with osteoporosis who have experienced osteoporotic fractures if they remain at high risk after 3–5 years of taking them. An electronic search of electronic databases was conducted, as well as a hand search of journals. A total of 94 publications were examined. 17 publications were included in the review. We concluded that patients who stopped taking bisphosphonates had a 20–40% higher risk of new clinical fractures and nearly twice the risk of vertebral fractures compared with the treatment period, indicating that a drug holiday is recommended not for all patients receiving therapy. However, long-term therapy with alendronate and zoledronic acid has been shown to reduce the risk of fractures in women with osteoporosis. The persistent increase in spinal bone mineral density with long-term bisphosphonate use may explain the lower incidence of vertebral fractures in patients on therapy long-term compared with patients who discontinued therapy after 3 years.
About the Authors
L. A. Marchenkova
National Medical Research Center of Rehabilitation and Balneology
Russian Federation
Competing Interests:
Russian Federation
Larisa A. Marchenkova - Dr. Sci. (Med.).
121099, Moscow, Novy Arbat st., 32
Researcher ID I-7220-2017; Scopus Author ID 57195620774
Competing Interests:
None
V. A. Vasileva
National Medical Research Center of Rehabilitation and Balneology
Russian Federation
Competing Interests:
Russian Federation
Valeriia A. Vasileva - Ph.D. (Med.).
Moscow
Scopus Author ID 57226068483
Competing Interests:
None
References
1. Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update. J Clin Endocrinol Metab. 2020;105(3):587-594. doi: https://doi.org/10.1210/clinem/dgaa048
2. Dennison EM, Cooper C, Kanis JA, et al. Fracture risk following intermission of osteoporosis therapy. Osteoporos Int. 2019;30(9):1733-1743. doi: https://doi.org/10.1007/s00198-019-05002-w
3. Eastell R, Hannon RA, Wenderoth D, Rodriguez-Moreno J, Sawicki A. Effect of Stopping Risedronate after Long-Term Treatment on Bone Turnover. J Clin Endocrinol Metab. 2011;96(11):3367-3373. doi: https://doi.org/10.1210/jc.2011-0412
4. Black DM, Schwartz A V., Ensrud KE, et al. Effects of Continuing or Stopping Alendronate After 5 Years of Treatment. JAMA. 2006;296(24):2927. doi: https://doi.org/10.1001/jama.296.24.2927
5. Белая Ж.Е., Белова К.Ю., Бирюкова Е.В., Дедов И.И., и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза // Остеопороз и остеопатии. — 2021. — Т. 24. — No2. — С. 4-47. doi: https://doi.org/10.14341/osteo12930
6. Belaya Z, Rozhinskaya L, Dedov I, et al. A summary of the Russian clinical guidelines on the diagnosis and treatment of osteoporosis. Osteoporos Int. 2023;34(3):429-447. doi: https://doi.org/10.1007/s00198-022-06667-6
7. Bone HG, Hosking D, Devogelaer J-P, et al. Ten Years’ Experience with Alendronate for Osteoporosis in Postmenopausal Women. N Engl J Med. 2004;350(12):1189-1199. doi: https://doi.org/10.1056/NEJMoa030897
8. Tonino RP. Skeletal Benefits of Alendronate: 7-Year Treatment of Postmenopausal Osteoporotic Women. J Clin Endocrinol Metab. 2000;85(9):3109-3115. doi: https://doi.org/10.1210/jc.85.9.3109
9. Cummings SR. Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral Fractures<SUBTITLE>Results From the Fracture Intervention Trial</SUBTITLE>. JAMA. 1998;280(24):2077. doi: https://doi.org/10.1001/jama.280.24.2077
10. Quandt SA, Thompson DE, Schneider DL, Nevitt MC, Black DM. Effect of Alendronate on Vertebral Fracture Risk in Women With Bone Mineral Density T Scores of −1.6 to −2.5 at the Femoral Neck: The Fracture Intervention Trial. Mayo Clin Proc. 2005;80(3):343-349. doi: https://doi.org/10.4065/80.3.343
11. Ryder KM, Cummings SR, Palermo L, et al. Does a history of non-vertebral fracture identify women without osteoporosis for treatment? J Gen Intern Med. 2008. doi: https://doi.org/10.1007/s11606-008-0622-0
12. Donaldson MG, Palermo L, Ensrud KE, Hochberg MC, Schousboe JT, Cummings SR. Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: The fracture intervention trial. J Bone Miner Res. 2012. doi: https://doi.org/10.1002/jbmr.1625
13. Bauer DC, Garnero P, Hochberg MC, et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: The fracture intervention trial. J Bone Miner Res. 2006. doi: https://doi.org/10.1359/JBMR.051018
14. Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27(2):243-254. doi: https://doi.org/10.1002/jbmr.1494
15. Black DM, Reid IR, Cauley JA, et al. The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2015;30(5):934-944. doi: https://doi.org/10.1002/jbmr.2442
16. Reid IR, Horne AM, Mihov B, et al. Fracture Prevention with Zoledronate in Older Women with Osteopenia. N Engl J Med. 2018;379(25):2407-2416. doi: https://doi.org/10.1056/NEJMoa1808082
17. Miller PD, Recker RR, Reginster J-Y, et al. Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study. Osteoporos Int. 2012;23(6):1747-1756. doi: https://doi.org/10.1007/s00198-011-1773-0
18. Bianchi G, Czerwinski E, Kenwright A, Burdeska A, Recker RR, Felsenberg D. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. Osteoporos Int. 2012;23(6):1769-1778. doi: https://doi.org/10.1007/s00198-011-1793-9
Review
For citations:
Marchenkova L.A., Vasileva V.A. Long-term therapy with bisphosphonates: review of clinical studies. Osteoporosis and Bone Diseases. 2023;26(4):4-7. (In Russ.) https://doi.org/10.14341/osteo13143
Views:
410
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
